top of page
483,000
Number of women with HER2+ Breast Cancer
in the United States and European Union[4]
Anchor 1

THERANOSTIC SPOTLIGHT
A combined therapeutic and diagnostic approach
for breast cancer
By integrating imaging and targeted radiotherapy, we are pioneering a personalized approach to the management of each patient's condition using a novel method called theranostics.
AIP is on the frontier of molecular drug development.
95%
of rare diseases have not one single
FDA approved drug treatment[3]
1.1 million
Oncology and Rare Pediatric Patients whose quality of life will benefit from solutions
delivered by our pipeline
bottom of page